SKU LUM-SS31-10 · C₃₂H₄₉N₉O₅ · 639.79 g/mol · CAS 736992-21-5
A cell-permeable mitochondria-targeted tetrapeptide that selectively binds cardiolipin and reduces mitochondrial reactive-oxygen-species generation.
Purity (HPLC)
≥ 99.15%
Net peptide
5.00 mg ± 2%
Endotoxin
< 0.5 EU/mg
Format
Lyophilized vial
Storage
−20 °C, desiccated
Shelf life
24 months from MFG
$150CAD/ 50 mg vial
In stock · Lot 26-A031
Qty
Add $300 for Free shipping
HPLC + MS verified per lot
~4 days typical to your door
COA bundled with shipment
Lot retains kept 5 years
Overview
SS-31 (elamipretide) is a cell-permeable synthetic tetrapeptide that concentrates 1000-fold inside the inner mitochondrial membrane via cardiolipin binding. The peptide stabilizes cardiolipin in the cristae, supporting electron-transport-chain assembly and reducing reactive-oxygen-species leak.
Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped ~4 days typical from our lab.
Research applications
Mitochondrial cardiolipin-binding assays, ETC supercomplex assembly investigations, ischemia-reperfusion in-vitro models, and bioenergetic profiling of aged or stressed cell lines.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
Identity
Parameter
Value
Sequence
D-Arg-Dmt-Lys-Phe-NH₂
Molecular formula
C₃₂H₄₉N₉O₅
Molecular weight
639.79 g/mol
CAS number
736992-21-5
Length
4 residues (cell-permeable)
Quality
Test
Specification
HPLC purity
99.18%
Mass confirmation
ESI-MS within 0.5 Da
Net peptide content
≥ 80% by AAA
Endotoxin
< 0.5 EU/mg (LAL)
Bioburden
< 10 CFU/g
Residual TFA
< 1.0%
Lot LM-2779
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Canada. Retain samples held under storage spec for five years from release date.
Verification
Method
Result
RP-HPLC at 220 nm
99.18% main peak
ESI-MS (positive)
639.8 Da (theor. 639.79)
Amino acid analysis
82.1% net peptide
LAL endotoxin
< 0.05 EU/mg
Karl Fischer (water)
2.8% w/w
Reconstitution
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Storage after reconstitution
Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Selected references
Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050.
Birk AV et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria. J Am Soc Nephrol. 2013;24(8):1250–1261.
Mitchell W et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics. J Biol Chem. 2020;295(21):7452–7469.
Shipped in ~4 days typical via Xpresspost from Canada
Background research
What the literature says about Ss 31.
Mechanism
Ss 31 is a mitochondrial-targeted peptide, classified within the cardiolipin protection pathway. Structurally it is a tetrapeptide D-Arg-2',6'-Dmt-Lys-Phe-NH₂. SS-31 (elamipretide) is a mitochondrially-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. Szeto and Birk (2014) characterized its protective effect on mitochondrial structure and function.
In an in-vitro setting, Ss 31 interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable until reconstituted.
Common research applications
In-vitro receptor-binding and dose-response screens against the cardiolipin protection target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Ss 31's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.
Storage & handling
Ss 31 arrives lyophilized in Canada Post (~4 days typical). On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
References
Szeto HH, Birk AV. Clin Pharmacol Ther. 2014;96(6):672-83.
Karaa A et al. Neurology. 2018;90(14):e1212-21.
Birk AV et al. J Am Soc Nephrol. 2013;24(8):1250-61.
For laboratory research only. Ss 31 is sold strictly as an in-vitro reference standard. Sold as an in-vitro reference standard, not as a Health Canada or FDA-approved therapeutic.
